Also known as: ceralasertib
Lynparza is the brand name for olaparib, a poly ADP-ribose polymerase (PARP) inhibitor used across multiple BRCA/HRR-associated cancers. Its indications include ovarian, fallopian tube, peritoneal, breast, pancreatic, and prostate cancers in specific biomarker-defined settings. The FDA first approved Lynparza on December 19, 2014.
PARP inhibitors remain strongest in BRCA1/2-altered tumors as use beyond that group has been uneven. In June 2025, the FDA narrowed Zejula’s first-line ovarian maintenance indication to HRD-positive tumors only.
Dizal's Phase III trial of Zegfrovy for first-line NSCLC with EGFR exon20ins met its primary endpoint, showing improved progression-free survival. Meanwhile, Immutep halted its Phase III eftilagimod alfa trial, and AstraZeneca's LATIFY trial of ceralasertib plus Imfinzi failed to meet its overall survival endpoint.
Whole genome sequencing, comprehensive genomic profiling, and spatial multiomics are transforming precision medicine from research tools to clinical applications in oncology, rare diseases, and neonatal care, enabling faster diagnoses and personalized treatments.
The FDA has granted fast track designation to ART6043 plus olaparib for germline BRCA-mutated HER2-negative breast cancer and to BriaCell's Bria-IMT plus immune checkpoint inhibitor for metastatic breast cancer, both addressing significant unmet medical needs.
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07460180 |
The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07407452 |
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07382544 |
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss |
RECRUITING | PHASE1 |
| NCT07024784 |
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies |
RECRUITING | PHASE2 |
| NCT06966700 |
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) |
RECRUITING | PHASE3 |
| NCT06915025 |
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer |
RECRUITING | PHASE3 |
| NCT06909825 |
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06856499 |
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer |
RECRUITING | PHASE1 |
| NCT06797635 |
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) |
RECRUITING | PHASE2 |
| NCT06783127 |
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer |
RECRUITING |
